In a filing with the Taiwan Stock Exchange, HTC said it would buy 5.33 million shares in US-based OnLive at $7.50 per share as part of a partnership.

The first tranche for Tracon Pharmaceuticals is $14m to fund the development of the antibody TRC105 through its phase two trials.

Third Rock led last year's $35m B round that also saw biotech company Genzyme's corporate venturing division join the investment consortium as a new investor and it remains on the company's share register, although not publicly mentioned in its latest $30m C round.

In July, Lockerz raised an undisclosed amount of venture capital from venture capital firm Kleiner Perkins Caufield & Byers and Nasdaq-listed Liberty Media's Interactive division. Liberty on its website said it owned 65% of Lockerz.

Energy Technology Ventures, a General Electric-NRG Energy-ConocoPhillips joint venture, and Aster Capital, backed by European industrial groups Alstom, Schneider Electric and Rhodia, are two funds backing Ioxus, a US-based battery maker.

Alongside SR One backing F-star are Germany-based drugs maker Merck Serono's corporate venturing unit, MP Healthcare Venture, a jointly owned subsidiary of Mitsubishi Tanabe Pharma and its parent company Mitsubishi Chemical, and venture capital firms Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.

SingTel Innov8, the corporate venturing unit of Singapore-based phone operator SingTel Group, backs US-based network equipment maker Capella Intelligent Subsystems.

Intel Capital's investment is part of $30m round for Kno, which also sees Advance Publications join the consortium as a new investor.

Tactics II Stem Cell Ventures, a venture capital firm set up by Robert and Thomas Palay after they sold NimbleGen Systems to Switzerland-based drugs company Roche in August 2007 for $272.5m, led the round for Cellular Dynamics International .

Alongside Safeguard in the PixelOptics round was venture capital firms Delphi Ventures, Carlyle Group, Longitude Capital and Stark Investments.